Although it is still unclear if SPEG is also a negative regulator of dynamin 2, gene silencing of DNM2 may be a potential therapeutic approach for CNM caused by variants in DNM2 gene as well as for CNM associated with variants in other genes such as MTM1, BIN1, SPEG. This evidence concerns the gene MTM1 and centronuclear myopathy.